Diamyd Medical is a Swedish diabetes company active in the field of pharmaceutical development. Diamyd Medical develops the diabetes vaccine Diamyd®, an Antigen Based Therapy (ABT) based on the exclusively in-licensed GAD molecule. In-licensed technologies for GABA and Gliadin also have potential to become a key piece of the puzzle of a future solution to prevent, treat or cure autoimmune diabetes and other inflammation-related conditions. Diamyd Medical's share is traded on Nasdaq Stockholm First North, ticker DMYD B.
Diamyd Medical Address
Kungsgatan 29 Stockholm, null SWE
Diamyd Medical Email
Past Companies
Diamyd MedicalUS Site Relations and Patient Recruitment Lead
Independent consultantClinical Consultant for clinical trials/medical device industry